Pancreatic Cancer Research

ResearcherInstitute of Science TokyoActive in the last 2 years

Shinji Tanaka

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7718-3453; OpenAlex author ID A5060197046, A5120950060. Sources: OpenAlex.

Their work

Papers
15 (first author 2, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
36
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: 3 papers · 2017: none · 2018: none · 2019: none · 2020: 1 paper · 2021: 5 papers · 2022: none · 2023: 3 papers · 2024: none · 2025: 1 paper · 2026: 1 paper

Papers 15

  1. Cytokine mRNA-based therapy alleviates dendritic cell and T cell paucity to eliminate aggressive pancreatic cancer in preclinical mouse models. Last author DOI 10.1016/j.ebiom.2026.106137↗
  2. PAD2-Mediated Histone Citrullination Drives Tumor Progression by Enhancing Cell Proliferation and Modifying the Microenvironment in Pancreatic Cancer. Last author DOI 10.1158/1541-7786.mcr-24-1095↗
  3. Identification of a novel target of SETD1A histone methyltransferase and the clinical significance in pancreatic cancer. Last author DOI 10.1111/cas.15615↗
  4. A niche-mimicking polymer hydrogel-based approach to identify molecular targets for tackling human pancreatic cancer stem cells. Co-author DOI 10.1186/s41232-023-00296-0↗
  5. RRM1 is mediated by histone acetylation through gemcitabine resistance and contributes to invasiveness and ECM remodeling in pancreatic cancer. Co-author DOI 10.3892/ijo.2023.5499↗
  6. Extraordinary first jejunal arterial variation associated with annular pancreas undergoing pancreaticoduodenectomy for pancreatic cancer: a case report. Co-author DOI 10.1007/s00276-020-02671-9↗
  7. C646 inhibits G2/M cell cycle-related proteins and potentiates anti-tumor effects in pancreatic cancer. Co-author DOI 10.1038/s41598-021-89530-8↗
  8. Inhibition of acid ceramidase elicits mitochondrial dysfunction and oxidative stress in pancreatic cancer cells. Co-author DOI 10.1111/cas.15123↗
  9. Prediction of early recurrence of pancreatic ductal adenocarcinoma after resection. Co-author DOI 10.1371/journal.pone.0249885↗
  10. Cytoplasmic RRM1 activation as an acute response to gemcitabine treatment is involved in drug resistance of pancreatic cancer cells. Co-author DOI 10.1371/journal.pone.0252917↗
  11. Successful conversion surgery of distal pancreatectomy with celiac axis resection (DP-CAR) with double arterial reconstruction using saphenous vein grafting fo… Co-author DOI 10.1186/s40792-020-01082-7↗
  12. Clinical application of the biomarkers for the selection of adjuvant chemotherapy in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/jhbp.366↗
  13. Molecular Pathogenesis and Targeted Therapy of Pancreatic Cancer. Co-author DOI 10.1245/s10434-015-4463-x↗
  14. Dominant Expression of DCLK1 in Human Pancreatic Cancer Stem Cells Accelerates Tumor Invasion and Metastasis. First author DOI 10.1371/journal.pone.0146564↗
  15. Identification of pancreatic cancer stem cells and selective toxicity of chemotherapeutic agents. First author DOI 10.1053/j.gastro.2012.03.054↗

Closest collaborators

The 25 strongest of 36 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Minoru Tanabe · 10 shared papers, 2016–2025 · strength 1.22
  2. Daisuke Ban · 10 shared papers, 2012–2026 · strength 1.16
  3. Hiroaki Ono · 7 shared papers, 2020–2025 · strength 0.97
  4. Kosuke Ogawa · 6 shared papers, 2020–2023 · strength 0.78
  5. Shuichi Watanabe · 5 shared papers, 2020–2023 · strength 0.65
  6. Kentaro Umemura · 2 shared papers, 2025–2026 · strength 0.42
  7. Yosuke Igarashi · 2 shared papers, 2025–2026 · strength 0.42
  8. Yoshiaki Tanji · 2 shared papers, 2025–2026 · strength 0.42
  9. Tomotaka Kato · 3 shared papers, 2021–2023 · strength 0.40
  10. Yoshiki Murase · 3 shared papers, 2020–2023 · strength 0.37
  11. Toru Ikegami · 2 shared papers, 2021–2026 · strength 0.33
  12. Daisuke Asano · 2 shared papers, 2023 · strength 0.31
  13. Toshiro Ogura · 2 shared papers, 2021 · strength 0.24
  14. Yuki Mochida · 1 shared paper, 2026 · strength 0.22
  15. Aya Maekawa · 2 shared papers, 2020–2021 · strength 0.22
  16. Yuji Soejima · 1 shared paper, 2025 · strength 0.19
  17. Kouichi Tabu · 1 shared paper, 2023 · strength 0.18
  18. Yoshitaka Murota · 1 shared paper, 2023 · strength 0.18
  19. Ayano Kabashima · 1 shared paper, 2023 · strength 0.16
  20. Takeshi Ishii · 1 shared paper, 2023 · strength 0.16
  21. Yasuhito Iwao · 1 shared paper, 2021 · strength 0.15
  22. Krishna V Menon · 1 shared paper, 2021 · strength 0.15
  23. Toshitaka Sugawara · 1 shared paper, 2021 · strength 0.12
  24. Hiromichi Ito · 1 shared paper, 2021 · strength 0.11
  25. Tomohiko Taniai · 1 shared paper, 2021 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.